[HTML][HTML] Investigational drug treatments for triple-negative breast cancer
C Damaskos, N Garmpis, A Garmpi… - Journal of personalized …, 2021 - mdpi.com
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …
[HTML][HTML] Atovaquone suppresses triple-negative breast tumor growth by reducing immune-suppressive cells
A major contributing factor in triple-negative breast cancer progression is its ability to evade
immune surveillance. One mechanism for this immunosuppression is through ribosomal …
immune surveillance. One mechanism for this immunosuppression is through ribosomal …
Carrier-free core–shell nanodrugs for synergistic two-photon photodynamic therapy of cervical cancer
Carrier-free nanodrugs named BCNPs were prepared by the coassembly of 2, 5-bis (4-
(diethylamino) benzylidene) cyclopentanone (BDBC) and curcumin (CCM) in the absence of …
(diethylamino) benzylidene) cyclopentanone (BDBC) and curcumin (CCM) in the absence of …
[PDF][PDF] Некоторые молекулярные и иммунологические факторы прогноза трижды негативного рака молочной железы
КС Титов, АМ Казаков, МА Барышникова… - Онкогинекология, 2019 - osors.ru
Заключение. Агрессивное течение и неблагоприятный прогноз при ТНРМЖ диктуют
необходимость в более глубоком изучении его биологических особенностей …
необходимость в более глубоком изучении его биологических особенностей …
Imunomodulação do microambiente do câncer de mama por nanopartículas de HA-PEI-PLGA-MTX combinado ao anti-PD-L1 via supressão do eixo de sinalização IL …
RS Cavalcante - 2020 - repositorio.ufrn.br
RESUMO A inflamação associada ao microambiente tumoral no câncer de mama triplo
negativo está intimamente relacionada ao desenvolvimento e progressão do tumor. Nesse …
negativo está intimamente relacionada ao desenvolvimento e progressão do tumor. Nesse …
Investigation of the Cancer Testis Antigen Prame as a Novel Regulator of Immune Evasion in Triple Negative Breast Cancer
RAKM Bacha - 2019 - search.proquest.com
Background: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype
characterized by absence of estrogen receptor (ER), progesterone receptor (PR) and human …
characterized by absence of estrogen receptor (ER), progesterone receptor (PR) and human …